CN106389395A - Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) - Google Patents
Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) Download PDFInfo
- Publication number
- CN106389395A CN106389395A CN201610919143.1A CN201610919143A CN106389395A CN 106389395 A CN106389395 A CN 106389395A CN 201610919143 A CN201610919143 A CN 201610919143A CN 106389395 A CN106389395 A CN 106389395A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- ibs
- bowel syndrome
- irritable bowel
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
Abstract
The invention discloses a use of resveratrol in preparation of a drug for treating irritable bowel syndrome (IBS). A study finds that an IBS patient has symptoms of high intestinal sensitivity and intestinal motility reduction and resveratrol can significantly reduce high intestinal sensitivity of IBS patients and can significantly reverse the weakening of intestinal power. The invention provides a basis for use of resveratrol as a safe and effective drug for treating IBS.
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of new medicine use of resveratrol and in particular to resveratrol is in system
Application in standby treatment irritable bowel syndrome medicine.
Background technology
Irritable bowel syndrome (irritable bowel syndrome, IBS) is common gastrointestinal function disease, with
Stomachache or abdominal discomfort, companion's bowl evacuation habit and stool are characterized extremely, and prevalence is about 11%.Because disease is in slow
Property and repeated relapsing, IBS patients ' life quality is generally reduced, and its high prevalence and the very long course of disease cause great society
And financial burden.So its pathogenesis not yet illustrates completely.Instestinal motility is abnormal and the high sensitivity of internal organs is two pathology main greatly
Physiological foundation.
Resveratrol (Resveratrol) is a kind of polyphenols being present in natural plants, is mainly derived from Portugal
The plants such as grape (red wine), Rhizoma Polygoni Cuspidati, Semen arachidis hypogaeae, Fructus Mori.Resveratrol has fat-soluble, the features such as easily pass through blood brain barrier.This
Invention is tested to IBS animal model by resveratrol, in conjunction with the detection such as Instestinal motility and visceral sensitivity, finds white Herba chenopodii
Reed alcohol can be used in the medicine of preparation treatment irritable bowel syndrome as effective ingredient.
Content of the invention
Present invention aims to the deficiencies in the prior art, provide a kind of new medicine use of resveratrol, that is,:In vain
Application in preparation treatment irritable bowel syndrome medicine for the veratryl alcohol.
By application in preparation treatment irritable bowel syndrome medicine for the resveratrol, can effectively reduce the intestinal of IBS patient
Road hypersensitivity simultaneously can significantly reverse weakening of Instestinal motility, and resveratrol can be applicable to the treatment IBS of brain intestinal double target spot effect
Safely and effectively medicine.
Brief description
Fig. 1 is the impact to IBS model mice body weight for the resveratrol.
Fig. 2 is the impact to IBS model mice visceral sensitivity for the resveratrol.
Fig. 3 is the impact to IBS model mice food coloring ink propulsive rate for the resveratrol.
Specific embodiment
With reference to specific pharmacological evaluation and result, the present invention will be further described.
First, materials and methods
(1) experiment material
1. laboratory animal
Male ICR mouse, body weight 26-33g.Mouse feeder is in USA New York state university Buffalo school district Animal House.Raise
Foster condition is as follows:23~25 DEG C of temperature, humidity 40%~50%, natural lighting, ad lib, water inlet.All mices are prior to raising
Adapt to 3 days in foster environment, then start zoopery again.Zoopery obtains relevant medical Ethics Committee on request and agrees to.
2. experimental drug
Resveratrol (resveratrol), rolipram (rolipram), desmethylimipramine (despramin) He Dixi
Dissolve (diazepam) and be purchased from Sigma Co., USA.All reagent are all dissolved in the physiology aqueous solution of 5%DMSO.Wherein, depressed
Related positive control drug is imipramine, and the related positive control drug of anxiety is diazepam, and rolipram is phosphodiesterase 4
(PDE4) inhibitor, the latter will be further used as mechanism target spot and carry out preliminary comparative study.
3. experiment equipment
Catheter.
(2) experimental technique
A. animal selects and packet
ICR mice is randomly divided into 8 groups, every group 12.Normal group, slowly acute joint Stress model group, resveratrol
Effect group (point basic, normal, high three various dose, respectively 2.5,5,10mg/kg, gavage) and positive controls (cough up Li Pu
Orchid, 1.25mg/kg, lumbar injection, desmethylimipramine, 10mg/kg, lumbar injection, diazepam, 0.5mg/kg, lumbar injection).
In addition to Normal group, remaining group all carry out slowly acute joint stress, that is, setting up classical acute slowly joint stress mice mould
Intend IBS model.
B. experimental procedure
1. set up slowly acute joint stress Model with Irritable Bowel Syndrome (chronic acute combining stress,
CACS)
IBS rat model adopts acute slowly joint Stress model (the chronic acute that Qian Jiaming team sets up
Combining stress, CACS), this model is to give acute constraint on the basis of chronic unpredictability Stress model to answer
Swash, simulation IBS patient long-term chronic stress descend because indivedual accidents aggravation situation, compared to mother-baby separation etc. other
Animal model, can the more preferable many-side IBS disease such as simulation Instestinal motility and Psychology and behavior.Set up that classical acute slowly combine should
Sharp IBS model (CACS):Giving chronic unpredictability gently stress totally 21 days, and following every 7 is a cycle.At the 13rd day and
After chronic unpredictability gently stress terminate in 21 days the 2nd day, then give Restraint Stress 6h.Chronic unpredictability gently stress
Program:(1) 4 DEG C of ice room 15 minutes;(2) food deprivation 4 hours;(3) tilt cage 4 hours;(4) water deprivation 4 hours;(5) tide
Wet bedding and padding 2 hours;(6) 12 DEG C of water temperatures are swum 5 minutes;(7) Restraint Stress 2 hours;(8) pressure tail 5 minutes;(9) food and water stripping
Take 6 hours by force;(10) shock by electricity 3 minutes;(11) 12 DEG C of water temperatures are swum 10 minutes;(12) illumination is overnight;(13) moist bedding and padding 4 hours;
(14) pressure tail 10 minutes;(15) Restraint Stress 3 hours;(16) moist bedding and padding 6 hours;(17) shock by electricity 6 minutes;(18) Restraint Stress
4 hours;(19) moist bedding and padding are overnight.During modeling, Normal group and model group give the physiology aqueous solution of 5%DMSO, its
His group gives corresponding medicine according to packet, continuous 26 days.
2. visceral sensitivity experiment
Visceral sensitivity detects:Expansion animal Colon and rectum, can cause its stomach wall to shrink, referred to as stomach wall withdraws reflection
(abdominal withdrawal reflex,AWR).AWR is the involuntary movement reflection similar with visceromotor reflex, can
Reflection internal organs sensitivity, is widely used for because it is non-invasive carrying out pluck sensitivity scoring.Also take stomach wall bag
The method burying electrode is detected, although but this detection can obtain objective data, due to being invasive, invasive inspection
Survey, for functional disease research, we are also intended to take AWR to be scored.
Before mouse experiment, fasting can't help water 12h so as to discharge remaining feces.Mice with after ether light anaesthesia, from anal
Inserting induction stimulates proctectasia (CRD) expansion catheter (6Fr, 2 mm outer diameter).After mice revival adapts to one hour, pass through
Syringe gas injection increases balloon pressure, gives 0.25ml by syringe respectively, and the air of 0.35ml, 0.5ml, 0.65ml enters
The air bag of catheter, respectively in triplicate, the stomach wall observing and recording mice withdraws reflection to each different pressures, is shown in Table 1.
Table 1:Mouse web portion withdraws reflection grade form
3. Instestinal motility experiment
Instestinal motility detects:Because IBS often shows, Instestinal motility is abnormal, and we adopt carbon powder method to detect Instestinal motility
Situation.
Before all mice detections, fasting 24 hours.Mice, with food coloring gavage, puts to death mice after 30 minutes.Open abdomen
Chamber, cuts off mesentery, stretches intestinal tube, the length of measurement pylorus to rectum and food coloring displacement.
Food coloring ink propulsive rate (%)=(distance/small intestinal total length of food coloring front end and pylorus) × 100%.System
Meter credit analysis carries out statistical procedures using GraphPad Prism 6.0 statistical package, and data is represented with mean ± SEM.Just
Often adopt t check analyses between matched group and stress group, medicine effect and its group difference adopt in One-wayANOVA
Dunnett ' st inspection is analyzed.
2nd, result
1. the impact to IBS model mice body weight for the resveratrol
Compared with Normal group, there was no significant difference for IBS model mice body weight (P > 0.05).Give resveratrol
After (2.5,5 and 10mg/kg), compared with stress group, there was no significant difference for medication group Mouse Weight, is shown in Table 1 and Fig. 1.
The impact to IBS model mice body weight for table 1 resveratrol
Control | Stress | REV2.5 | REV5 | REV10 | Rol | Despramin | Diazepam |
33±0.7977 | 30.4±1.067 | 31.45±0.6791 | 32.45±0.5934 | 32.18±0.9612 | 32.27±0.6754 | 32.82±0.872 | 32.09±0.8029 |
Fig. 1 is the impact to IBS model mice body weight for the resveratrol, compared with Normal group, IBS model mice body weight
There was no significant difference.IBS mice after resveratrol process, improved by body weight, but no difference of science of statistics.Rolipram, go
What first imipramine and diazepam were processed stress be after mice administration, and its body weight is relative to IBS model mouse there was no significant difference (P >
0.05).N=12, Mean ± SEM.
2. the impact to IBS model mice visceral sensitivity for the resveratrol
Result shows, compared with Normal group, the intestinal sensitivity of IBS model mice is giving 0.5ml and 0.65ml
(P < 0.0001, P < 0.0001) is significantly raised during air.And giving IBS model mice resveratrol (2.5,5 and 10mg/
Kg, after), the visceral sensitivity of mice reduces.And when giving 0.35m, 0.5ml, 0.65ml air detection, resveratrol is each
The effect of group significantly reduces the visceral sensitivity of IBS model mice.
The impact to IBS model mice visceral sensitivity for table 2. resveratrol
gas vol(ml) | Control | Stress | REV2.5 | REV5 | REV10 |
0.25 | 0.3333±0.1231 | 0.6061±0.1609 | 0.3889±0.06901 | 0.3889±0.0902 | 0.3889±0.2203 |
0.35 | 1.083±0.0131 | 1.455±0.1369 | 0.9444±0.0803* | 0.9722±0.0643 | 1±0.1925 |
0.5 | 1.722±0.0991 | 2.545±0.1293#### | 1.722±0.135*** | 1.833±0.0962** | 1.889±0.1319* |
0.65 | 2.389±0.0902 | 3.818±0.0525#### | 3.417±0.1095 | 3±0.1589*** | 3.056±0.0803** |
The impact (Continued) to IBS model mice visceral sensitivity for table 2. resveratrol
gas vol(ml) | Rol | Despramin | Diazepam |
0.25 | 0.5278±0.1714 | 0.1667±0.0649 | 0.3333±0.07107 |
0.35 | 1.139±0.215 | 0.75±0.1015** | 0.8611±0.0643* |
0.5 | 2.472±0.2301 | 1.889±0.1553* | 1.778±0.06268** |
0.65 | 3.194±0.207* | 2.667±0.1692**** | 2.75±0.117**** |
Fig. 2 be the impact to IBS model mice visceral sensitivity for the resveratrol, A, B, C, D represent respectively give 0.25ml,
During 0.35ml, 0.5ml, 0.65ml air, the intestinal sensitivity of mice.N=12, Mean ± SEM.***P < 0.001vs non-
stressed vehicle group;#P < 0.05,###P < 0.001vs vehicle-treated stressed group.
3. the impact to IBS model mice Instestinal motility for the resveratrol
Result shows, compared with Normal group, in IBS model edible color food coloring ink propulsive rate significantly reduce (##
P < 0.01).After giving resveratrol 23 days, the 5 IBS model mices processing with 10mg/kg resveratrol compare IBS model
Mice, its food coloring ink propulsive rate dramatically increases (P < 0.01, P < 0.001).Through rolipram, desmethylimipramine,
After process is dissolved in west, it dramatically increases (P < 0.001, P < 0.05, P < 0.0001) using pigment ink propulsive rate.
The impact to IBS model mice food coloring ink propulsive rate for table 3. resveratrol
Control | Stress | REV2.5 | REV5 | REV10 | Rol | Despramin | Diazepam |
62.95±3.681 | 47.31±3.101## | 52.6±5.979 | 68.04±3.919** | 72.72±3.963*** | 70.38±1.233*** | 65.46±3.823* | 71.55±4.29**** |
Fig. 3 is the impact to IBS model mice food coloring ink propulsive rate for the resveratrol, n=12, Mean ± SEM.##P
< 0.01vs non-stressed vehicle group;*P < 0.05,**P < 0.01,***P < 0.001,****P <
0.0001vs vehicle-treated stressed group.
3rd, study brief summary
The studies above shows, in terms of visceral sensitivity, gives slightly significantly to raise after large quantity of air in intestinal, high, normal, basic three
The resveratrol of individual dosage all can reduce the intestinal hypersensitivity of IBS model mice.In terms of Instestinal motility, IBS model mice
Show weakening of Instestinal motility, middle high dose resveratrol significantly reverses weakening of Instestinal motility.Illustrate that IBS mice has intestinal
Road hypersensitivity and Instestinal motility slow down, and resveratrol can reverse these changes above-mentioned.This is studied as resveratrol conduct
The safely and effectively medicine for the treatment of IBS provides experimental basis.
Claims (1)
1. application in preparation treatment irritable bowel syndrome medicine for the resveratrol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610919143.1A CN106389395A (en) | 2016-10-21 | 2016-10-21 | Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610919143.1A CN106389395A (en) | 2016-10-21 | 2016-10-21 | Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106389395A true CN106389395A (en) | 2017-02-15 |
Family
ID=58012455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610919143.1A Pending CN106389395A (en) | 2016-10-21 | 2016-10-21 | Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106389395A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014075124A1 (en) * | 2012-11-15 | 2014-05-22 | Victoria University | Methods and compositions for the treatment and/or prevention of bowel disorders |
CN103845311A (en) * | 2012-11-28 | 2014-06-11 | 青岛恒润源通果蔬专业合作社 | New medical use of resveratrol |
CN104739812A (en) * | 2015-02-10 | 2015-07-01 | 河北工业大学 | Pharmaceutical composition containing resveratrol and application of pharmaceutical composition |
-
2016
- 2016-10-21 CN CN201610919143.1A patent/CN106389395A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014075124A1 (en) * | 2012-11-15 | 2014-05-22 | Victoria University | Methods and compositions for the treatment and/or prevention of bowel disorders |
CN103845311A (en) * | 2012-11-28 | 2014-06-11 | 青岛恒润源通果蔬专业合作社 | New medical use of resveratrol |
CN104739812A (en) * | 2015-02-10 | 2015-07-01 | 河北工业大学 | Pharmaceutical composition containing resveratrol and application of pharmaceutical composition |
Non-Patent Citations (2)
Title |
---|
刘兵等: "白藜芦醇治疗腹泻型肠易激综合征的价值", 《胃肠病学和肝病学杂志》 * |
陆小锋等: "白藜芦醇对肠易激综合征影响的研究进展", 《实用医学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102028812B (en) | Chinese medicinal preparation for treating allergic rhinitis, allergic asthma and urticaria and preparation method thereof | |
CN102462825B (en) | Compound traditional Chinese medicine for treating depression | |
Dawud et al. | Effects of aqueous extract of Allium cepa (red onion) on ovalbumininduced allergic asthma in wistar rats | |
CN101843682A (en) | Maxingshigan injecta and preparation method thereof | |
CN106389395A (en) | Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) | |
CN103655544B (en) | The application of Jaceosidin in preparation prevention or the Fibrotic medicine for the treatment of chronic hepatic injury regulating liver-QI | |
CN104998277B (en) | A kind of resisting toxoplasmosis prescription medicine and its screening technique | |
CN104436150A (en) | Traditional Chinese medicine composition used for treating rhinitis | |
CN104436062A (en) | Traditional Chinese medicine composition for treating bovine grainsick and preparation method of traditional Chinese medicine composition | |
CN101485721A (en) | Chinese medicinal composition for resisting allergic rhinitis | |
CN102836203B (en) | Traditional Chinese medicine composition for treating wind-heat type common cold as well as preparation method and application thereof | |
CN103860894B (en) | A kind of medicine for the treatment of chronic prostatitis | |
CN103040939B (en) | Traditional Chinese medicine composition for treating cold, as well as preparation method and application thereof | |
CN105982908A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of drugs for treating constipation | |
CN104324209B (en) | One kind treats snorting Chinese medicine composition of pig and preparation method thereof | |
CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
CN102258615B (en) | Yanning capsule and preparation method thereof | |
CN105250700A (en) | Traditional Chinese medicine for treating chronic obstructive emphysema and preparation method thereof | |
CN116602945A (en) | Application of fennel ketone in preparing medicament for treating constipation type irritable bowel syndrome | |
CN101612160B (en) | Application of 20(S)-ginsenoside Rh2 compound in preparing antidepressant medicament | |
CN104586913A (en) | Application of safflower organic solvent part extract in preparation of airway smooth muscle relaxation medicines | |
CN1951464A (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
CN105168201A (en) | Application of vitexin in preparation of drug for treating postoperative pain | |
CN104306470A (en) | Medicine composition for treating primary dysmenorrhea | |
CN105535065A (en) | Medicine composition for treating schizophrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |